Moreover, we observed significant elevation of tumor-infiltrating CD3+, CD4+, and CD8 + T cells but not CD11B + myloid cells in mice administered combination therapy, suggesting that strategies co-blocking MET and PD-L1 synergistically potentiate anti-tumor immunity in mice (Fig. 6F-G, Figure S5A-5B). This evidence concerns the gene CD4 and neoplasm.